On June 22, 2026, the U.S. Food and Drug Administration issued a revised draft guidance, Master Protocols for Drug and Biological Product Development, updating the version FDA first proposed in December 2023 under docket FDA-2023-D-5259. The revision responds to stakeholder feedback on the 2023 draft and adds substantially more detail on basket trials, an area the original draft addressed only lightly compared with its coverage of umbrella and platform trial designs.
A note on timing: some trackers circulating this guidance have cited a comment deadline of July 24, 2026. Based on the Federal Register notice publishing the revised draft and subsequent regulatory-affairs reporting, the actual public comment period runs through August 24, 2026 — a roughly two-month window from the notice’s late-June publication. Research offices working from an internal calendar entry dated July 24 should correct it; the window is still open as of this writing, but by a smaller margin than the original entry suggested.
What the revised draft covers
This is a cross-cutting guidance: unlike FDA’s 2022 final guidance on master protocols specifically for oncology drugs and biologics, the document at docket FDA-2023-D-5259 applies to master-protocol trials across drug and biological product development generally. It lays out FDA’s current thinking on design and analysis considerations for trials run under a single master protocol, including:
- Randomization approaches and control-group selection when arms are added or dropped over time
- Blinding to treatment assignment across multiple concurrent sub-studies
- Informed consent practices for master-protocol structures, including re-consent as arms change
- Adaptive design elements and interim decision rules
- Statistical multiplicity when a protocol evaluates several drugs, diseases, or disease subtypes at once
- Comparisons between investigational drugs studied under the same protocol
- Approaches for evaluating a single drug’s effect across multiple diseases, conditions, or disease subtypes — the basket-trial-specific content that is new to this revision
- Trial oversight structures, data sharing, and dissemination of results across a multi-arm, multi-sponsor, or multi-indication protocol
- What sponsors should include in regulatory submissions built on master-protocol data
Together these design types are often grouped as master protocols: a single overarching protocol that governs multiple sub-studies or treatment arms, whether that means one drug tested across several diseases sharing a biomarker (a basket trial), several drugs tested against one disease (an umbrella trial), or an open-ended, perpetual structure where arms are added and removed over the life of the trial (a platform trial). FDA’s use of Bayesian adaptive design methods is common across all three, and the revised draft’s multiplicity and control-group guidance speaks directly to how those methods get evaluated at submission.
Why it matters for research administrators and CRAs
Master protocols already create administrative complexity that a traditional single-arm, single-sponsor trial doesn’t: a single ICH E6(R2)-compliant oversight structure has to accommodate arms that open and close on different timelines, often under a single IND with amendments filed as arms change rather than a fresh submission per arm. For institutions and CROs operating as sites within a master-protocol trial, that structure has direct operational consequences:
- IRB and reliance agreements need to be built to accommodate mid-study amendments adding or closing arms, not just a one-time initial review — central or single-IRB review under an arrangement such as SMART IRB is common precisely because re-reviewing every site for every arm change doesn’t scale.
- Budgeting and contracting get harder when a site doesn’t know at activation how many arms it will ultimately participate in, or for how long — a live issue for anyone negotiating a clinical trial agreement against a master protocol rather than a fixed-scope study.
- Trial Master File organization has to track documentation per sub-study/arm as well as at the master-protocol level, which affects how a TMF is structured from the outset.
- Consent management for participants who may be reassigned, or whose arm closes mid-study, needs a defined process before the trial opens, not improvised after the fact.
A finalized version of this guidance — once FDA closes comment, reviews submissions, and issues a final document, a process that typically takes many months to a year or more after a comment period closes — would give sponsors, CROs, and institutional research offices a more predictable regulatory basis for structuring these agreements and IRB workflows. That’s the practical reason this draft is worth research administrators’ attention now, during the comment window, rather than waiting for a final guidance to appear.
Comment period status and how to comment
As of this writing, the comment period on the revised draft guidance is open. Comments can be submitted electronically through regulations.gov under docket number FDA-2023-D-5259, or in writing to the FDA Dockets Management Staff, referencing the same docket number and the guidance title. Because FDA guidance documents are non-binding and represent the agency’s current thinking rather than a final rule, comments submitted during this window are the primary formal channel institutions, sponsors, and professional associations have to influence the final text before it’s issued.
Research offices that operate or host master-protocol trials — particularly institutions running or participating in oncology basket/umbrella trials such as those built on precision-oncology screening protocols, or umbrella designs run through NCI-funded cooperative groups — are a natural constituency for comment, especially on the sections addressing IRB oversight, informed consent for arm changes, and data sharing across sub-studies.
Background: how this fits FDA’s broader master-protocol framework
FDA’s engagement with master-protocol design isn’t new. The agency finalized a narrower, oncology-specific guidance, Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics, in March 2022, following draft guidance first issued in 2018. The document revised in June 2026 is the broader, non-oncology-specific companion: FDA first proposed it in draft form in December 2023, and this revision — with its expanded basket-trial content — is the product of comments FDA received on that original 2023 draft. Readers wanting the underlying design concepts rather than the regulatory history can start with CASRAI’s definitions of basket trial, umbrella trial, and platform trial, or the broader clinical research pillar for how these designs fit into trial operations more generally.
This piece reflects publicly available Federal Register and FDA.gov material as of the date of publication. Comment period dates for FDA guidance documents can be extended; readers relying on this deadline for a submission should confirm current status directly on regulations.gov before finalizing a comment.
